含Jumonji结构域蛋白2B对肺腺癌切除患者的预后影响
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
作者信息
Toyokawa Gouji, Taguchi Kenichi, Edagawa Makoto, Shimamatsu Shinichiro, Toyozawa Ryo, Nosaki Kaname, Hirai Fumihiko, Yamaguchi Masafumi, Shimokawa Mototsugu, Seto Takashi, Takenoyama Mitsuhiro, Hamamoto Ryuji, Sugio Kenji, Ichinose Yukito
机构信息
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
Cancer Pathology Laboratory, National Kyushu Cancer Center, Fukuoka, Japan.
出版信息
Anticancer Res. 2016 Sep;36(9):4841-6. doi: 10.21873/anticanres.11046.
BACKGROUND
Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated.
PATIENTS AND METHODS
Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated.
RESULTS
Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor.
CONCLUSION
JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.
背景
含Jumonji结构域蛋白2B（JMJD2B）已被证明在肺癌细胞的发病机制中起重要作用。然而，JMJD2B在肺癌患者中的意义仍有待阐明。
患者与方法
本研究纳入了78例接受手术切除的腺癌患者，这些患者具有肺癌致癌驱动因素的数据。使用针对JMJD2B的特异性抗体进行免疫组织化学分析，以研究JMJD2B的表达情况，并评估JMJD2B表达在术后生存中的意义。
结果
在78例患者中，50例（64%）表现为JMJD2B免疫阳性。50例JMJD2B阳性患者术后的总生存期（OS）明显低于JMJD2B阴性患者（五年生存率=56.7%对92.6%；对数秩检验：p=0.01）。多因素分析表明，JMJD2B阳性是一个独立的预后因素。
结论
JMJD2B可能是手术切除的肺腺癌的一个新的预后因素。
Zotero 插件